De-Escalation Study Evaluating Venetoclax and Azacitidine Discontinuation in AML Responding Patients
Status:
RECRUITING
Trial end date:
2028-11-01
Target enrollment:
Participant gender:
Summary
The goal of this clinical trial is to test efficacy and safety of a VENETOCLAX-AZACITIDINE (VEN-AZA) de-escalation strategy in Acute Myeloid Leukemia responding patients. The main objectives of the study are:
* Evaluation of the efficacy of VEN-AZA de-escalation strategy by measuring the effect of VEN-AZA discontinuation in term of Disease-Free Survival.
* Evaluation of the other efficacy parameters and safety of VEN-AZA de-escalation strategy.
Patients from the prospective study will be compared to a retrospective cohort of patients who will be selected on the basis of identical eligibility criteria.
Participants will:
* Stop VEN-DASA treatment
* Be closely monitored by regular evaluation of the disease